A retrospective analysis compared outcomes of NPM1-mut AML patients treated with three different regimens (intensive chemotherapy, hypomethylating agents alone, and venetoclax plus hypomethylating agents): venetoclax plus hypomethylating agents improved OS compared to hypomethylating agents alone or to intensive chemotherapy [100]. The gene discussed is NPM1; the disease is acute myeloid leukemia.